William J. Galush
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
William J. Galush has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
Jamie M. R. Moore
Early Stage Pharmaceutical Development and ‡Protein Analytical Chemistry, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
1 shared publicationJun Ouyang
Early Stage Pharmaceutical Development and ‡Protein Analytical Chemistry, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
1 shared publicationLan N. Le
Early Stage Pharmaceutical Development, Genentech, Inc, South San Francisco, California 94080, United States
1 shared publicationMary D. H. Nguyen
Early Stage Pharmaceutical Development and ‡Protein Analytical Chemistry, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
1 shared publicationXiaoying Chen
Early Stage Pharmaceutical Development and ‡Protein Analytical Chemistry, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
1 shared publication
Latest Publications
- 22 August 2012
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 84 (17) , 7479-7486
Profiling Antibody Drug Conjugate Positional Isomers: A System-of-Equations Approach
Antibody drug conjugates enable the targeted delivery of potent chemotherapeutic agents directly to cancerous cells. They are made by the chemical conjugation of cytotoxins to monoclonal antibodies, which can be achieved by first reducing interchain disulfide bonds followed by conjugation of the resulting free thiols with drugs. This process yields a controlled, but heterogeneous, population of conjugated products that contains species with various numbers of drugs linked to different former interchain disulfide cysteine residues on the antibodies. We have developed a mathematical approach using inputs from capillary electrophoresis and hydrophobic interaction chromatography to determine the positional isomer distribution within a population of antibody drug conjugates. The results are confirmed by analyzing isolated samples of specific drug-to-antibody ratio species. The procedure is amenable to rapid determination of positional isomer distributions and features low material requirements. A survey of several antibody drug conjugates based on the same IgG framework and small molecule drug combination has shown a very similar distribution of isomers among all of the molecules using this technique, suggesting a robust conjugation process.
- 22 August 2012
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 84 (17) , 7479-7486
Profiling Antibody Drug Conjugate Positional Isomers: A System-of-Equations Approach
Antibody drug conjugates enable the targeted delivery of potent chemotherapeutic agents directly to cancerous cells. They are made by the chemical conjugation of cytotoxins to monoclonal antibodies, which can be achieved by first reducing interchain disulfide bonds followed by conjugation of the resulting free thiols with drugs. This process yields a controlled, but heterogeneous, population of conjugated products that contains species with various numbers of drugs linked to different former interchain disulfide cysteine residues on the antibodies. We have developed a mathematical approach using inputs from capillary electrophoresis and hydrophobic interaction chromatography to determine the positional isomer distribution within a population of antibody drug conjugates. The results are confirmed by analyzing isolated samples of specific drug-to-antibody ratio species. The procedure is amenable to rapid determination of positional isomer distributions and features low material requirements. A survey of several antibody drug conjugates based on the same IgG framework and small molecule drug combination has shown a very similar distribution of isomers among all of the molecules using this technique, suggesting a robust conjugation process.